Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

Overview

House Resolution 1285 (HRES 1285), introduced in the 119th Congress, expresses the sense of the House of Representatives regarding the safety, effectiveness, and accessibility of mifepristone, a medication used for abortion care. The resolution emphasizes that more than 25 years of real-world evidence and hundreds of peer-reviewed studies support mifepristone’s safety and effectiveness, and it calls for law and policy governing access to this time-sensitive medication abortion care to be equitable, transparent, and science-based. The measure is non-binding and reflects a congressional statement of priorities rather than new law.

Purpose and Intent

• Acknowledges and affirms the safety and effectiveness of mifepristone based on decades of real-world experience and peer-reviewed research.
• Urges that laws, regulations, and policies governing access to mifepristone be aligned with the best available scientific evidence.
• Calls for approaches to medication abortion access that are equitable and transparent, reducing barriers and ensuring timely care.

Key Provisions

As a House Resolution, HRES 1285 does not enact new statutory requirements or create enforceable federal programs. Instead, its core elements are:

• A statement of support for mifepristone’s safety and efficacy, citing more than 25 years of evidence.
• A call for policy and regulatory frameworks to reflect science-based, evidence-informed decisionmaking.
• Emphasis on ensuring access to time-sensitive medication abortion in a manner that is fair and transparent.

Who/What Is Affected

• The resolution signals congressional intent to influence how federal, state, and possibly local policies consider mifepristone access.
• It may affect policymakers, healthcare providers, patients seeking medication abortion, and organizations involved in reproductive health policy by signaling support for evidence-based practices.

Procedural and Timeline Aspects

• Action History: On May 14, 2026, HRES 1285 was referred to the House Committee on Energy and Commerce and was submitted in the House.
• Next steps (typical for such resolutions): committee consideration, potential markup, and floor consideration. As a non-binding sense-of-the-House measure, it does not become law but can guide legislative priorities and influence ongoing policy debates.

Potential Impact

• Sets a formal legislative position favoring science-based access to mifepristone.
• Could shape the framing of future regulations, oversight, and funding decisions related to medication abortion.
• Signals bipartisan or cross-partisan interest in aligning policy with substantial medical evidence, potentially affecting regulatory discussions at agencies overseeing reproductive health care.

If you’d like, I can add context comparing this resolution to prior related measures or outline potential policy avenues it could influence (e.g., FDA-related guidance, state-access regulations, or access programs).